| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 8,300.0 | 7,769.0 |
| Profit before tax | 3,063.0 | 3,641.0 |
| Net income | 2,429.0 | 3,052.0 |
| EPS (diluted, $ a share) | $1.94 | $2.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -20.4% |
|---|---|
| Revenue, year on year | +6.8% |
| Operating margin | 41.7% |
10-Q filed with the SEC, NASDAQ: GILD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Gilead Sciences, Inc.: key numbers
- Share price
- $167.58Close, Nov 16
- Market cap
- $208B
- Shares outstanding
- 1.24BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Gilead Sciences, Inc.
All →Gilead Sciences Insider Kelly A. Kramer Sells $1.76M of Stock
Kelly A. Kramer sold 10,376 shares of Gilead Sciences, Inc. at $168.23 to $171.44 a share (average $169.76) in 4 transactions, worth $1.76M in total on Nov 12, 2026. Shares held after the trade: 1,339 (-13.0%).
- Value
- $1.76M
- Shares
- 10,376
- Average price
- $169.76
- Holding change
- -13.0%
- Trade date
- Nov 12, 2026
Gilead Sciences EVP Gen Counsel, Legal & Comp Wettan Keeley M. Cain Sells $558K of Stock
Wettan Keeley M. Cain, EVP Gen Counsel, Legal & Comp, sold 3,399 shares of Gilead Sciences, Inc. at $164.11 a share, worth $558K in total on Nov 6, 2026. Shares held after the trade: 5,360 (-38.8%).
- Value
- $558K
- Shares
- 3,399
- Price
- $164.11
- Role
- EVP Gen Counsel, Legal & Comp
- Holding change
- -38.8%
- Trade date
- Nov 6, 2026
Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $19.7M of Stock
Daniel Patrick O'Day, Chairman & CEO, sold 112,429 shares of Gilead Sciences, Inc. at $175.16 to $175.17 a share (average $175.16) in 2 transactions, worth $19.7M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 551,683 (-1.7%).
- Value
- $19.7M
- Shares
- 112,429
- Average price
- $175.16
- Role
- Chairman & CEO
- Holding change
- -1.7%
- Trade date
- Nov 4, 2026 to Nov 5, 2026
Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $5.33M of Stock
Daniel Patrick O'Day, Chairman & CEO, sold 30,881 shares of Gilead Sciences, Inc. at $167.40 to $175.25 a share (average $172.57) in 6 transactions, worth $5.33M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 551,683 (-0.4%).
- Value
- $5.33M
- Shares
- 30,881
- Average price
- $172.57
- Role
- Chairman & CEO
- Holding change
- -0.4%
- Trade date
- Oct 30, 2026 to Nov 2, 2026
Gilead Sciences Earnings Call: Key Takeaways
Gilead delivered record 16% base business growth driven by HIV and Oncology, though management faces a significant $1.5 billion revenue headwind in 2028 due to Medicare price setting for Biktarvy.
- Call
- Oct 29, 2026, 4:30 PM ET
Gilead Sciences Financial Results
Gilead Sciences reported third-quarter 2026 financial results, featuring a 13% increase in total product sales to $8.3 billion, driven by strong performance in its HIV portfolio. The company raised its full-year base business revenue guidance for the second time this year, citing robust demand for Biktarvy and HIV prevention products.
“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.”
Daniel O’Day, Gilead’s Chairman and Chief Executive Officer
“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026.”
Daniel O’Day, Gilead’s Chairman and Chief Executive Officer